150 research outputs found
Development of effective antimicrobial nanocomposites / nanomaterials
Microbial infections have a long history of causing serious illnesses for human and animals. The presence of harmful bacteria, especially on the surface of the objects and equipment in hospitals, causes many mortalities for ill patients and is a major global challenge. The inappropriate usage of antibiotics has lead to antimicrobial resistance development in bacteria. The global concern about antimicrobial resistance has triggered the development of new and more effective antimicrobial agents. A promising method is the use of novel nanomaterials against bacteria in a rapid way so that these bacteria may not be able to develop resistance. The nanoparticles (NPs) possess enhanced physicochemical properties compared with their bulk counterparts owing to a high surface to volume ratio. The metal and metal oxide nanoparticles (NPs) such as Ag, Cu and TiOâ NPs have proven to be effective in killing bacteria through various mechanisms such as ion originating from the dissolution of NPs and reactive oxygen species (ROS) generated from the photocatalytic process. This research project is focused on synthesizing of effective antimicrobial nanocomposites/nanomaterials with novel characteristics such as rapidness, multi-mode mechanisms and induction in the visible light range.Thesis (MPhil) -- University of Adelaide, School of Chemical Engineering, 201
Lanthanide-doped upconversion nanoparticles (UCNPs) for biomedical applications
This thesis examines the need for new antibacterial materials to treat small colony variants
(SCVs) of Staphylococcus (S.) aureus bacteria and their parental strains. While ZnO-based
nanoparticles (NPs) activated by ultraviolet (UV) and short wavelength visible light have been
researched for their antibacterial properties, the potential benefits of incorporating UCNPs to
allow activation by near-infrared (NIR) light have been overlooked. This study aims to fill this
research gap by comprehensively investigating the synthesis and performance of ZnO-coated
lanthanide-doped upconversion nanoparticle (UCNP) composites activated by NIR light
against S. aureus SCVs and parental strains.
Furthermore, this research addresses the limited understanding of the potential risks associated
with UV emission from UCNPs used as fluorescent probes in super-resolution microscopy
(SRM). Despite extensive research on the usage of UCNPs as fluorescent probes for SRMs,
the potential cytotoxic effects of UV emission from UCNPs have not been thoroughly studied.
To advance cellular imaging techniques and ensure cellular viability, a comprehensive
investigation of UV emission from UCNPs is necessary. This thesis aims to identify and
quantify UV emission by UCNPs used in SRM and develop strategies to minimise UV
emission and mitigate potential cytotoxic effects.
These two main aims are addressed in three results chapters. The first aim, the focus of chapters
2 and 3, focuses on the synthesis UCNP@ZnO composites that can be activated by NIR light
for antimicrobial photodynamic therapy (aPDT) applications against S. aureus SCVs and
parental strains. Chapter 2 reports the synthesis and performance of these composites, showing
these materials to be effective antibacterial therapies against S. aureus SCVs, while chapter 3
improves upon the performance of these composites by careful tuning of the UCNP core and
provides enhancements to the ZnO shell composition to improve reactive oxygen species
generation and add a second mode of action in the form of silver nanoparticles. The second
aim of this research is covered in chapter 4, which reports an investigation into the UV emission
from UCNPs used as fluorescent probes in SRM. The work posits the need to understand the
UV emission properties of these UCNPs as knowledge of these and the potential for cytotoxic
effects are crucial for optimizing cellular imaging experiments and ensuring accurate and
reliable results. Chapter 4 identifies design features and compositions that can limit UV
emission, thereby minimizing the risk of phototoxicity and advancing the field of cellular
imaging.
Overall, the findings from this research have the potential to contribute to the development of
safer and more effective targeted antibacterial therapies and enhance the understanding of UV
emissions in cellular imaging techniques.Thesis (Ph.D.) -- University of Adelaide, School of Chemical Engineering, 202
Multiwalled Carbon Nanotubes and Nitric Oxide Modulate the Germination and Early Seedling Growth of Barley under Drought and Salinity
To evaluate the impacts of various concentrations of multiwalled carbon nanotubes (0, 500, 1000 and 2000 mg L-1) and sodium nitroprusside (0 and 100 ÎŒM as nitric oxide (NO) donor) on seed germination and early seedling growth of barley, two separate factorial experiments were conducted based on a randomized complete block design under polyethylene glycol-simulated drought stress and NaCl salinity stress conditions. Based on the results, a concentration-dependent declining trend was observed in barley germination indices upon seed exposure to polyethylene glycol (PEG) and NaCl suspensions. Employing multiwalled carbon nanotubes (MWCNTs) particularly 1000 and 500 mg L-1 and sodium nitroprusside (SNP) alleviated the adverse impacts of drought and salinity stresses. However, applied MWCNTs and SNP together were more efficient than suspension alone. The combined application of MWCNTs with SNP increased germination percentage, germination rate, root length, shoot length, vigor index and decreased mean germination time of barley. Similarly, the amount of moisture content and uniformity of seed germination were obviously increased by MWCNTs and SNP under drought and salinity. In contrast, MWCNTs at 2000 mg L-1 had an inhibitory impact on barley seed germination, while use of SNP moderated adverse effects of MWCNTs. Generally, it can be concluded that appropriate concentration of MWCNTs is beneficial in improving drought and NaCl salinity tolerance of barley by boosting seed water absorption and increasing the moisture content of seedlings
Power Law Nanofluid through Tapered Artery based on a âConsistent Couple Stress Theory
Based on couple stress theory, this study investigated non-Newtonian power-law nanofluid flows in converging, non-tapered, and diverging arteries. In addition to excluding gravity effects artery, geometry included mild stenosis. The momentum equation is solved via the Galerkin method, and the results are compared with experimental and classical findings. Although the power-law couple stress theoryâs relations are first used in the analysis of non-Newtonian blood flow, the results of this theory are far more consistent with experimental results than classical results. Comparison of the results of the study of blood flow velocity profiles in a non-tapered artery without stenosis by the mentioned theory with experimental and classical theory results shows the difference in velocity at the center of the artery between the experimental results and the results of the classical theory is 36%, while this value has been reduced to 14% for the results of the couple stress theory. The variations in velocity profile with the power-law index (n=0.8 and n=0.85) and the dimensionless Darcy number (Da=10-10 and Da=10-7) in all three geometries indicated a flat velocity distribution with the increase in the power-law index while increasing the velocity profile with increased Darcy number. Mass transfer and energy equations are solved using the extended Kantorovich method. The solution convergence is evaluated, and the influence of parameters such as Prandtl number, Schmidt number, and dimensionless thermospheric and Brownian parameters on concentration and temperature profiles is obtained
Mapping 123 million neonatal, infant and child deaths between 2000 and 2017
Since 2000, many countries have achieved considerable success in improving child survival, but localized progress remains unclear. To inform efforts towards United Nations Sustainable Development Goal 3.2âto end preventable child deaths by 2030âwe need consistently estimated data at the subnational level regarding child mortality rates and trends. Here we quantified, for the period 2000â2017, the subnational variation in mortality rates and number of deaths of neonates, infants and children under 5 years of age within 99 low- and middle-income countries using a geostatistical survival model. We estimated that 32% of children under 5 in these countries lived in districts that had attained rates of 25 or fewer child deaths per 1,000 live births by 2017, and that 58% of child deaths between 2000 and 2017 in these countries could have been averted in the absence of geographical inequality. This study enables the identification of high-mortality clusters, patterns of progress and geographical inequalities to inform appropriate investments and implementations that will help to improve the health of all populations
Mapping local patterns of childhood overweight and wasting in low- and middle-income countries between 2000 and 2017
A double burden of malnutrition occurs when individuals, household members or communities experience both undernutrition and overweight. Here, we show geospatial estimates of overweight and wasting prevalence among children under 5 years of age in 105 low- and middle-income countries (LMICs) from 2000 to 2017 and aggregate these to policy-relevant administrative units. Wasting decreased overall across LMICs between 2000 and 2017, from 8.4% (62.3 (55.1â70.8) million) to 6.4% (58.3 (47.6â70.7) million), but is predicted to remain above the World Health Organizationâs Global Nutrition Target of <5% in over half of LMICs by 2025. Prevalence of overweight increased from 5.2% (30 (22.8â38.5) million) in 2000 to 6.0% (55.5 (44.8â67.9) million) children aged under 5 years in 2017. Areas most affected by double burden of malnutrition were located in Indonesia, Thailand, southeastern China, Botswana, Cameroon and central Nigeria. Our estimates provide a new perspective to researchers, policy makers and public health agencies in their efforts to address this global childhood syndemic
Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017 : a systematic analysis for the Global Burden of Disease Study 2017
Background: The Global Burden of Diseases, Injuries, and Risk Factors Study 2017 (GBD 2017) includes a comprehensive assessment of incidence, prevalence, and years lived with disability (YLDs) for 354 causes in 195 countries and territories from 1990 to 2017. Previous GBD studies have shown how the decline of mortality rates from 1990 to 2016 has led to an increase in life expectancy, an ageing global population, and an expansion of the non-fatal burden of disease and injury. These studies have also shown how a substantial portion of the world's population experiences non-fatal health loss with considerable heterogeneity among different causes, locations, ages, and sexes. Ongoing objectives of the GBD study include increasing the level of estimation detail, improving analytical strategies, and increasing the amount of high-quality data. Methods: We estimated incidence and prevalence for 354 diseases and injuries and 3484 sequelae. We used an updated and extensive body of literature studies, survey data, surveillance data, inpatient admission records, outpatient visit records, and health insurance claims, and additionally used results from cause of death models to inform estimates using a total of 68 781 data sources. Newly available clinical data from India, Iran, Japan, Jordan, Nepal, China, Brazil, Norway, and Italy were incorporated, as well as updated claims data from the USA and new claims data from Taiwan (province of China) and Singapore. We used DisMod-MR 2.1, a Bayesian meta-regression tool, as the main method of estimation, ensuring consistency between rates of incidence, prevalence, remission, and cause of death for each condition. YLDs were estimated as the product of a prevalence estimate and a disability weight for health states of each mutually exclusive sequela, adjusted for comorbidity. We updated the Socio-demographic Index (SDI), a summary development indicator of income per capita, years of schooling, and total fertility rate. Additionally, we calculated differences between male and female YLDs to identify divergent trends across sexes. GBD 2017 complies with the Guidelines for Accurate and Transparent Health Estimates Reporting. Findings: Globally, for females, the causes with the greatest age-standardised prevalence were oral disorders, headache disorders, and haemoglobinopathies and haemolytic anaemias in both 1990 and 2017. For males, the causes with the greatest age-standardised prevalence were oral disorders, headache disorders, and tuberculosis including latent tuberculosis infection in both 1990 and 2017. In terms of YLDs, low back pain, headache disorders, and dietary iron deficiency were the leading Level 3 causes of YLD counts in 1990, whereas low back pain, headache disorders, and depressive disorders were the leading causes in 2017 for both sexes combined. All-cause age-standardised YLD rates decreased by 3·9% (95% uncertainty interval [UI] 3·1â4·6) from 1990 to 2017; however, the all-age YLD rate increased by 7·2% (6·0â8·4) while the total sum of global YLDs increased from 562 million (421â723) to 853 million (642â1100). The increases for males and females were similar, with increases in all-age YLD rates of 7·9% (6·6â9·2) for males and 6·5% (5·4â7·7) for females. We found significant differences between males and females in terms of age-standardised prevalence estimates for multiple causes. The causes with the greatest relative differences between sexes in 2017 included substance use disorders (3018 cases [95% UI 2782â3252] per 100 000 in males vs s1400 [1279â1524] per 100 000 in females), transport injuries (3322 [3082â3583] vs 2336 [2154â2535]), and self-harm and interpersonal violence (3265 [2943â3630] vs 5643 [5057â6302]). Interpretation: Global all-cause age-standardised YLD rates have improved only slightly over a period spanning nearly three decades. However, the magnitude of the non-fatal disease burden has expanded globally, with increasing numbers of people who have a wide spectrum of conditions. A subset of conditions has remained globally pervasive since 1990, whereas other conditions have displayed more dynamic trends, with different ages, sexes, and geographies across the globe experiencing varying burdens and trends of health loss. This study emphasises how global improvements in premature mortality for select conditions have led to older populations with complex and potentially expensive diseases, yet also highlights global achievements in certain domains of disease and injury. Funding: Bill & Melinda Gates Foundation
Global injury morbidity and mortality from 1990 to 2017 : results from the Global Burden of Disease Study 2017
Correction:Background Past research in population health trends has shown that injuries form a substantial burden of population health loss. Regular updates to injury burden assessments are critical. We report Global Burden of Disease (GBD) 2017 Study estimates on morbidity and mortality for all injuries. Methods We reviewed results for injuries from the GBD 2017 study. GBD 2017 measured injury-specific mortality and years of life lost (YLLs) using the Cause of Death Ensemble model. To measure non-fatal injuries, GBD 2017 modelled injury-specific incidence and converted this to prevalence and years lived with disability (YLDs). YLLs and YLDs were summed to calculate disability-adjusted life years (DALYs). Findings In 1990, there were 4 260 493 (4 085 700 to 4 396 138) injury deaths, which increased to 4 484 722 (4 332 010 to 4 585 554) deaths in 2017, while age-standardised mortality decreased from 1079 (1073 to 1086) to 738 (730 to 745) per 100 000. In 1990, there were 354 064 302 (95% uncertainty interval: 338 174 876 to 371 610 802) new cases of injury globally, which increased to 520 710 288 (493 430 247 to 547 988 635) new cases in 2017. During this time, age-standardised incidence decreased non-significantly from 6824 (6534 to 7147) to 6763 (6412 to 7118) per 100 000. Between 1990 and 2017, age-standardised DALYs decreased from 4947 (4655 to 5233) per 100 000 to 3267 (3058 to 3505). Interpretation Injuries are an important cause of health loss globally, though mortality has declined between 1990 and 2017. Future research in injury burden should focus on prevention in high-burden populations, improving data collection and ensuring access to medical care.Peer reviewe
Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990â2019 : a systematic analysis for the Global Burden of Disease Study 2019
Background: Achieving universal health coverage (UHC) involves all people receiving the health services they need, of high quality, without experiencing financial hardship. Making progress towards UHC is a policy priority for both countries and global institutions, as highlighted by the agenda of the UN Sustainable Development Goals (SDGs) and WHO's Thirteenth General Programme of Work (GPW13). Measuring effective coverage at the health-system level is important for understanding whether health services are aligned with countries' health profiles and are of sufficient quality to produce health gains for populations of all ages. Methods: Based on the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, we assessed UHC effective coverage for 204 countries and territories from 1990 to 2019. Drawing from a measurement framework developed through WHO's GPW13 consultation, we mapped 23 effective coverage indicators to a matrix representing health service types (eg, promotion, prevention, and treatment) and five population-age groups spanning from reproductive and newborn to older adults (>= 65 years). Effective coverage indicators were based on intervention coverage or outcome-based measures such as mortality-to-incidence ratios to approximate access to quality care; outcome-based measures were transformed to values on a scale of 0-100 based on the 2.5th and 97.5th percentile of location-year values. We constructed the UHC effective coverage index by weighting each effective coverage indicator relative to its associated potential health gains, as measured by disability-adjusted life-years for each location-year and population-age group. For three tests of validity (content, known-groups, and convergent), UHC effective coverage index performance was generally better than that of other UHC service coverage indices from WHO (ie, the current metric for SDG indicator 3.8.1 on UHC service coverage), the World Bank, and GBD 2017. We quantified frontiers of UHC effective coverage performance on the basis of pooled health spending per capita, representing UHC effective coverage index levels achieved in 2019 relative to country-level government health spending, prepaid private expenditures, and development assistance for health. To assess current trajectories towards the GPW13 UHC billion target-1 billion more people benefiting from UHC by 2023-we estimated additional population equivalents with UHC effective coverage from 2018 to 2023. Findings: Globally, performance on the UHC effective coverage index improved from 45.8 (95% uncertainty interval 44.2-47.5) in 1990 to 60.3 (58.7-61.9) in 2019, yet country-level UHC effective coverage in 2019 still spanned from 95 or higher in Japan and Iceland to lower than 25 in Somalia and the Central African Republic. Since 2010, sub-Saharan Africa showed accelerated gains on the UHC effective coverage index (at an average increase of 2.6% [1.9-3.3] per year up to 2019); by contrast, most other GBD super-regions had slowed rates of progress in 2010-2019 relative to 1990-2010. Many countries showed lagging performance on effective coverage indicators for non-communicable diseases relative to those for communicable diseases and maternal and child health, despite non-communicable diseases accounting for a greater proportion of potential health gains in 2019, suggesting that many health systems are not keeping pace with the rising non-communicable disease burden and associated population health needs. In 2019, the UHC effective coverage index was associated with pooled health spending per capita (r=0.79), although countries across the development spectrum had much lower UHC effective coverage than is potentially achievable relative to their health spending. Under maximum efficiency of translating health spending into UHC effective coverage performance, countries would need to reach adjusted for purchasing power parity) in order to achieve 80 on the UHC effective coverage index. From 2018 to 2023, an estimated 388.9 million (358.6-421.3) more population equivalents would have UHC effective coverage, falling well short of the GPW13 target of 1 billion more people benefiting from UHC during this time. Current projections point to an estimated 3.1 billion (3.0-3.2) population equivalents still lacking UHC effective coverage in 2023, with nearly a third (968.1 million [903.5-1040.3]) residing in south Asia. Interpretation: The present study demonstrates the utility of measuring effective coverage and its role in supporting improved health outcomes for all people-the ultimate goal of UHC and its achievement. Global ambitions to accelerate progress on UHC service coverage are increasingly unlikely unless concerted action on non-communicable diseases occurs and countries can better translate health spending into improved performance. Focusing on effective coverage and accounting for the world's evolving health needs lays the groundwork for better understanding how close-or how far-all populations are in benefiting from UHC
Population and fertility by age and sex for 195 countries and territories, 1950â2017: a systematic analysis for the Global Burden of Disease Study 2017
Background: Population estimates underpin demographic and epidemiological research and are used to track progress on numerous international indicators of health and development. To date, internationally available estimates of population and fertility, although useful, have not been produced with transparent and replicable methods and do not use standardised estimates of mortality. We present single-calendar year and single-year of age estimates of fertility and population by sex with standardised and replicable methods. Methods: We estimated population in 195 locations by single year of age and single calendar year from 1950 to 2017 with standardised and replicable methods. We based the estimates on the demographic balancing equation, with inputs of fertility, mortality, population, and migration data. Fertility data came from 7817 location-years of vital registration data, 429 surveys reporting complete birth histories, and 977 surveys and censuses reporting summary birth histories. We estimated age-specific fertility rates (ASFRs; the annual number of livebirths to women of a specified age group per 1000 women in that age group) by use of spatiotemporal Gaussian process regression and used the ASFRs to estimate total fertility rates (TFRs; the average number of children a woman would bear if she survived through the end of the reproductive age span [age 10â54 years] and experienced at each age a particular set of ASFRs observed in the year of interest). Because of sparse data, fertility at ages 10â14 years and 50â54 years was estimated from data on fertility in women aged 15â19 years and 45â49 years, through use of linear regression. Age-specific mortality data came from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017 estimates. Data on population came from 1257 censuses and 761 population registry location-years and were adjusted for underenumeration and age misreporting with standard demographic methods. Migration was estimated with the GBD Bayesian demographic balancing model, after incorporating information about refugee migration into the model prior. Final population estimates used the cohort-component method of population projection, with inputs of fertility, mortality, and migration data. Population uncertainty was estimated by use of out-of-sample predictive validity testing. With these data, we estimated the trends in population by age and sex and in fertility by age between 1950 and 2017 in 195 countries and territories. Findings: From 1950 to 2017, TFRs decreased by 49\ub74% (95% uncertainty interval [UI] 46\ub74â52\ub70). The TFR decreased from 4\ub77 livebirths (4\ub75â4\ub79) to 2\ub74 livebirths (2\ub72â2\ub75), and the ASFR of mothers aged 10â19 years decreased from 37 livebirths (34â40) to 22 livebirths (19â24) per 1000 women. Despite reductions in the TFR, the global population has been increasing by an average of 83\ub78 million people per year since 1985. The global population increased by 197\ub72% (193\ub73â200\ub78) since 1950, from 2\ub76 billion (2\ub75â2\ub76) to 7\ub76 billion (7\ub74â7\ub79) people in 2017; much of this increase was in the proportion of the global population in south Asia and sub-Saharan Africa. The global annual rate of population growth increased between 1950 and 1964, when it peaked at 2\ub70%; this rate then remained nearly constant until 1970 and then decreased to 1\ub71% in 2017. Population growth rates in the southeast Asia, east Asia, and Oceania GBD super-region decreased from 2\ub75% in 1963 to 0\ub77% in 2017, whereas in sub-Saharan Africa, population growth rates were almost at the highest reported levels ever in 2017, when they were at 2\ub77%. The global average age increased from 26\ub76 years in 1950 to 32\ub71 years in 2017, and the proportion of the population that is of working age (age 15â64 years) increased from 59\ub79% to 65\ub73%. At the national level, the TFR decreased in all countries and territories between 1950 and 2017; in 2017, TFRs ranged from a low of 1\ub70 livebirths (95% UI 0\ub79â1\ub72) in Cyprus to a high of 7\ub71 livebirths (6\ub78â7\ub74) in Niger. The TFR under age 25 years (TFU25; number of livebirths expected by age 25 years for a hypothetical woman who survived the age group and was exposed to current ASFRs) in 2017 ranged from 0\ub708 livebirths (0\ub707â0\ub709) in South Korea to 2\ub74 livebirths (2\ub72â2\ub76) in Niger, and the TFR over age 30 years (TFO30; number of livebirths expected for a hypothetical woman ageing from 30 to 54 years who survived the age group and was exposed to current ASFRs) ranged from a low of 0\ub73 livebirths (0\ub73â0\ub74) in Puerto Rico to a high of 3\ub71 livebirths (3\ub70â3\ub72) in Niger. TFO30 was higher than TFU25 in 145 countries and territories in 2017. 33 countries had a negative population growth rate from 2010 to 2017, most of which were located in central, eastern, and western Europe, whereas population growth rates of more than 2\ub70% were seen in 33 of 46 countries in sub-Saharan Africa. In 2017, less than 65% of the national population was of working age in 12 of 34 high-income countries, and less than 50% of the national population was of working age in Mali, Chad, and Niger. Interpretation: Population trends create demographic dividends and headwinds (ie, economic benefits and detriments) that affect national economies and determine national planning needs. Although TFRs are decreasing, the global population continues to grow as mortality declines, with diverse patterns at the national level and across age groups. To our knowledge, this is the first study to provide transparent and replicable estimates of population and fertility, which can be used to inform decision making and to monitor progress. Funding: Bill & Melinda Gates Foundation
- âŠ